IMTX Stock Risk & Deep Value Analysis
Immatics NV
DVR Score
out of 10
What You Need to Know About IMTX Stock
We analyzed Immatics NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IMTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IMTX Risk Analysis & Red Flags
What Could Go Wrong
Failure of lead clinical programs (IMA203, IMA401) to demonstrate sufficient efficacy or safety in ongoing trials would severely diminish the company's prospects, leading to substantial stock price decline and difficulty securing future funding. A major clinical setback could reduce market cap by 50%+.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Deep unprofitability and consistent cash burn necessitating future capital raises.
- ⚠
Significant clinical trial risks inherent in oncology cell therapy development.
Upcoming Risk Events
- 📅
Negative or unclear clinical trial results at ASCO or future readouts
- 📅
Regulatory delays or setbacks for lead programs
When to Reconsider
- 🚪
Negative or equivocal clinical data readouts that do not meet efficacy or safety expectations.
- 🚪
Excessive share dilution (e.g., >20% in a single financing round) without clear clinical progression.
- 🚪
Major regulatory setbacks or clinical holds on key programs.
Unlock IMTX Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Immatics NV offers a high-risk, high-reward opportunity leveraging its innovative XPRESIDENT platform for PRAME-targeted immunotherapies in solid tumors. With strong clinical catalysts (ASCO 2026) and a major partnership, the company is poised for significant re-rating if upcoming data confirms efficacy and safety, unlocking substantial future market leadership in a critical oncology space.
Is IMTX Stock Undervalued?
Unlock the full AI analysis for IMTX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IMTX Price Targets & Strategy
12-Month Target
$19.00
Bull Case
$25.00
Bear Case
$8.00
Valuation Basis
Based on median analyst price target and discounted future pipeline value, typical for clinical-stage biotechnology with significant catalysts.
Entry Strategy
Consider dollar-cost averaging near current levels ($10-$11) or on any dip prior to ASCO 2026 for opportunistic entry.
Exit Strategy
Take profit on significant positive clinical readouts or upon reaching analyst targets (e.g., $18-$20). Set a stop loss below recent support, possibly $9 if clinical news disappoints.
Portfolio Allocation
7-15% for aggressive risk tolerance due to the high-risk, high-reward nature of clinical-stage biotech.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is IMTX Financially Healthy?
Valuation
P/E Ratio
-5.94
PEG Ratio
-0.30
Price/Book
1.00
Price/Sales
3.70
Profitability
Operating Margin
-377.10%
Net Margin
-407.00%
Return on Equity
-41.31%
Revenue Growth
-69.03%
EPS
$-1.61
Balance Sheet
Current Ratio
11.72
Quick Ratio
11.42
Debt/Equity
0.03
Other
Beta (Volatility)
1.30
Does IMTX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is durable as long as the XPRESIDENT platform continues to identify novel and effective targets, and the clinical pipeline progresses successfully. Patent protection on TCRs and bispecifics is key.
Moat Erosion Risks
- •Clinical failures or safety issues that invalidate the platform's potential.
- •Emergence of superior or more cost-effective technologies from competitors.
- •Challenges in manufacturing and scaling cell therapies.
IMTX Competitive Moat Analysis
Sign up to see competitive advantages
IMTX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data, but high-risk biotech often garners volatile sentiment)
Institutional Sentiment
Positive (TD Cowen and Jefferies initiated Buy coverage recently, offsetting Wall Street Zen downgrade to Sell).
Insider Activity (Form 4)
No specific Form 4 filings reported in the last 90 days. Institutional ownership at ~64%.
Options Flow
Normal options activity (no specific unusual activity reported).
Earnings Intelligence
Next Earnings
2026-05-12
Surprise Probability
Medium
Historical Earnings Pattern
Likely volatile reactions based on clinical progress updates and cash runway; Q4 2025 beat estimates, which could set a higher bar.
Key Metrics to Watch
Competitive Position
Top Competitor
Adaptimmune Therapeutics plc (ADAP) / Immunocore Holdings plc (IMCR)
Market Share Trend
N/A (pre-commercial, focused on gaining initial market validation through clinical success)
Valuation vs Peers
Difficult to compare directly due to different platforms and targets, but generally valued on pipeline potential similar to other clinical-stage oncology cell therapy developers.
Competitive Advantages
- •Proprietary XPRESIDENT platform for identifying novel intracellular targets.
- •Validated by significant partnership with Bristol Myers Squibb (BMS).
- •Diverse pipeline of TCR-T cell therapies and bispecifics.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive IMTX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 12, 2026)
- •ASCO 2026 Oral Presentations (May 29-Jun 2, 2026) for IMA203, IMA203CD8, IMA401, and synovial sarcoma TCR
Medium-Term (6-18 months)
- •Further clinical data readouts from ongoing trials (Phase 1/2 updates)
- •Potential expansion of BMS partnership or new strategic collaborations
Long-Term (18+ months)
- •Advancement of lead programs into pivotal trials
- •Potential regulatory submissions and commercialization of lead assets (post 2028)
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for IMTX?
- ✓
Positive clinical trial data from lead programs (e.g., objective response rates, duration of response).
- ✓
Updates on cash runway and future financing strategies.
- ✓
Expansion of existing partnerships or formation of new ones.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Immatics NV Makes Money
Immatics NV is a clinical-stage biotechnology company developing advanced T-cell receptor (TCR) engineered T cell immunotherapies and bispecifics to treat various solid tumors. They utilize their proprietary XPRESIDENT platform to discover novel, intracellular tumor targets, which are often inaccessible to conventional therapies, and then engineer highly specific T-cells or bispecific molecules to attack these targets. The company generates revenue primarily through collaboration agreements, milestone payments, and research funding from pharmaceutical partners as they advance their pipeline programs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Immatics NV (IMTX)?
As of May 6, 2026, Immatics NV has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Immatics NV?
Immatics NV's market capitalization is approximately $1.5B..
What is the risk level for IMTX stock?
Our analysis rates Immatics NV's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of IMTX?
Immatics NV currently has a price-to-earnings (P/E) ratio of -5.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Immatics NV's revenue growing?
Immatics NV has reported revenue growth of -69.0%. Revenue has been declining, which warrants closer examination.
Is IMTX stock profitable?
Immatics NV has a profit margin of -407.0%. The company is currently unprofitable.
How often is the IMTX DVR analysis updated?
Our AI-powered analysis of Immatics NV is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IMTX (Immatics NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.